Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

[Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea].

Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS; Korean College of Helicobacter and Upper Gastrointestinal Research; Korean Association of Gastroenterology.

Korean J Gastroenterol. 2009 Nov;54(5):269-78. Korean.

2.

The Korean perspective of Helicobacter pylori infection: lessons from the Japanese government's policy to prevent gastric cancer.

Park JM, Hahm KB.

Dig Dis. 2014;32(3):290-4. doi: 10.1159/000357861. Epub 2014 Apr 10. Review.

PMID:
24732195
3.

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.

Chey WD, Leontiadis GI, Howden CW, Moss SF.

Am J Gastroenterol. 2017 Feb;112(2):212-239. doi: 10.1038/ajg.2016.563. Epub 2017 Jan 10.

PMID:
28071659
4.

Bismuth-based therapies for the first step eradication of Helicobacter pylori.

Sezgin O, Altintaş E, Uçbilek E, Tataroğlu C.

Turk J Gastroenterol. 2006 Jun;17(2):90-3.

5.

[Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition].

Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC; Korean College of Helicobacter and Upper Gastrointestinal Research.

Korean J Gastroenterol. 2013 Jul;62(1):3-26. Korean.

6.

Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.

Lee HJ, Kim JI, Lee JS, Jun EJ, Oh JH, Cheung DY, Chung WC, Kim BW, Kim SS.

World J Gastroenterol. 2015 Jan 7;21(1):351-9. doi: 10.3748/wjg.v21.i1.351.

7.

Guidelines in the medical treatment of Helicobacter pylori infection.

Dzieniszewski J, Jarosz M.

J Physiol Pharmacol. 2006 Sep;57 Suppl 3:143-54.

PMID:
17033112
8.

Diagnosis and treatment of Helicobacter pylori infection.

Bytzer P, Dahlerup JF, Eriksen JR, Jarbøl DE, Rosenstock S, Wildt S; Danish Society for Gastroenterology.

Dan Med Bull. 2011 Apr;58(4):C4271. Review.

PMID:
21466771
9.

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ.

Gut. 2007 Jun;56(6):772-81. Epub 2006 Dec 14.

10.

Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.

Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD.

Am J Gastroenterol. 2010 Jan;105(1):65-73. doi: 10.1038/ajg.2009.508. Epub 2009 Sep 15. Review.

PMID:
19755966
11.

What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study.

Onal IK, Gokcan H, Benzer E, Bilir G, Oztas E.

Clin Res Hepatol Gastroenterol. 2013 Dec;37(6):642-6. doi: 10.1016/j.clinre.2013.05.005. Epub 2013 Jun 21.

PMID:
23796974
12.

Helicobacter pylori eradication therapy.

Suzuki H, Nishizawa T, Hibi T.

Future Microbiol. 2010 Apr;5(4):639-48. doi: 10.2217/fmb.10.25. Review.

PMID:
20353303
13.

Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.

Laine L, Estrada R, Trujillo M, Emami S.

Am J Gastroenterol. 1997 Dec;92(12):2213-5.

PMID:
9399755
14.

Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.

Gisbert JP, Perez-Aisa A, Rodrigo L, Molina-Infante J, Modolell I, Bermejo F, Castro-Fernández M, Antón R, Sacristán B, Cosme A, Barrio J, Harb Y, Gonzalez-Barcenas M, Fernandez-Bermejo M, Algaba A, Marín AC, McNicholl AG; H. pylori Study Group of the Spanish Gastroenterology Association.

Dig Dis Sci. 2014 Feb;59(2):383-9. doi: 10.1007/s10620-013-2900-x. Epub 2013 Oct 15.

PMID:
24126798
15.

The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea.

Chung JW, Lee GH, Han JH, Jeong JY, Choi KS, Kim DH, Jung KW, Choi KD, Song HJ, Jung HY, Kim JH.

Hepatogastroenterology. 2011 Jan-Feb;58(105):246-50.

PMID:
21510323
16.

The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.

Basyigit S, Kefeli A, Sapmaz F, Yeniova AO, Asilturk Z, Hokkaomeroglu M, Uzman M, Nazligul Y.

Bosn J Basic Med Sci. 2015 Oct 25;15(4):50-4. doi: 10.17305/bjbms.2015.573.

17.

Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.

Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren N.

Clin Ther. 2008 Mar;30(3):528-34. doi: 10.1016/j.clinthera.2008.03.009.

PMID:
18405790
18.

Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.

Köksal AS, Parlak E, Filik L, Yolcu OF, Odemiş B, Ulker A, Saşmaz N, Ozden A, Sahin B.

J Gastroenterol Hepatol. 2005 Apr;20(4):637-42.

PMID:
15836716
19.

Trends in the eradication rates of Helicobacter pylori infection for eleven years.

Yoon JH, Baik GH, Sohn KM, Kim DY, Kim YS, Suk KT, Kim JB, Kim DJ, Kim JB, Shin WG, Kim HY, Baik IH, Jang HJ.

World J Gastroenterol. 2012 Dec 7;18(45):6628-34. doi: 10.3748/wjg.v18.i45.6628.

20.

Supplemental Content

Support Center